Holen Sie sich die Stockscreener-App
1.29
4.03%
0.05
Handel nachbörslich:
1.29
Schlusskurs vom Vortag:
$1.24
Offen:
$1.26
24-Stunden-Volumen:
376.59K
Relative Volume:
0.40
Marktkapitalisierung:
$68.96M
Einnahmen:
Nettoeinkommen (Verlust:
$-78.34M
KGV:
-0.8705
EPS:
-1.4819
Netto-Cashflow:
$-75.02M
1W Leistung:
-13.42%
1M Leistung:
-5.15%
6M Leistung:
-8.51%
1J Leistung:
-10.42%
1-Tages-Spanne:
$1.24
$1.33
1-Wochen-Bereich:
$1.23
$1.55
52-Wochen-Spanne:
$1.02
$1.91
Pmv Pharmaceuticals Inc Stock (PMVP) Company Profile
Firmenname
Pmv Pharmaceuticals Inc
Sektor
Branche
Telefon
(609) 642-6670
Adresse
400 ALEXANDER PARK DRIVE, PRINCETON
Compare PMVP vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PMVP
Pmv Pharmaceuticals Inc
|
1.29 | 68.96M | 0 | -78.34M | -75.02M | -1.4819 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Pmv Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-07-08 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2024-11-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-05-13 | Eingeleitet | Craig Hallum | Buy |
| 2024-04-12 | Eingeleitet | Jefferies | Buy |
| 2023-12-27 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2022-03-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-09-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-08-19 | Eingeleitet | Oppenheimer | Perform |
| 2021-08-02 | Eingeleitet | Guggenheim | Buy |
| 2021-07-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-10-20 | Eingeleitet | BofA Securities | Buy |
| 2020-10-20 | Eingeleitet | Cowen | Outperform |
| 2020-10-20 | Eingeleitet | Evercore ISI | Outperform |
| 2020-10-20 | Eingeleitet | Goldman | Neutral |
Alle ansehen
Pmv Pharmaceuticals Inc Aktie (PMVP) Neueste Nachrichten
PMV Pharmaceuticals adds Matt Eckler and PMV Pharmaceuticals stock posts 21.60 percent YTD - ad-hoc-news.de
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know - Zacks Investment Research
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know - Yahoo Finance
PMV Pharmaceuticals: Restoring Mutant P53 Could Create A Mispriced Cancer Opportunity - Seeking Alpha
PMV Pharmaceuticals stock adds Matt Eckler to its board opening the next clinical chapter - AD HOC NEWS
PMV Pharmaceuticals stock adds Matt Eckler to its board opening the next clinical chapter - AD HOC NEWS
PMV PHARMACEUTICALS APPOINTS MATT ECKLER, PH.D., TO BOARD OF DIRECTORS - Moomoo
PMV Pharmaceuticals Appoints Matt Eckler to Board Ahead of 2027 NDA Filing - citybiz
PMV Pharmaceuticals Director Matthew Joseph Eckler Granted 84,000 Stock Options - Kalkine Media
PMV Pharmaceuticals Appoints Matthew Joseph Eckler as Director; Files Initial Ownership Statement with SEC - Kalkine Media
Phase 2 single-drug enrollment is complete. PMV Pharma (PMVP) plans an ovarian cancer drug application. - Stock Titan
PMV Pharmaceuticals adds biotech investor to its board - StreetInsider
PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors - Yahoo Finance
PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors - GlobeNewswire
A Q1 2027 application for accelerated approval is planned for PMV’s ovarian cancer drug. - Stock Titan
Biotech Stocks At 52-Week HighsKOD, MASS, OBIO, CDNA, PMVP - RTTNews
Pmv Pharmaceuticals Inc (NASDAQ: PMVP) Share Price, PMVP Stock News, PMVP Share Price & Updates - kalkine.ca
Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross? - Zacks Investment Research
Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross? - Yahoo Finance
An investor group in PMV Pharmaceuticals (NASDAQ: PMVP) is held just under a 10% stake by its warrant terms. - Stock Titan
PMV Pharma appoints Philip Herman as CCO - thepharmaletter.com
symbol__ Stock Quote Price and Forecast - cnn.com
H.C. Wainwright reiterates Buy on PMV Pharmaceuticals stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy on PMV Pharmaceuticals stock - Investing.com
H.C. Wainwright reiterates Buy on PMV Pharmaceuticals stock By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Buy on PMV Pharmaceuticals stock - Investing.com
PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer - Yahoo Finance
H.C. Wainwright reiterates Buy on PMV Pharmaceuticals stock By Investing.com - Investing.com Australia
PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer - GlobeNewswire
PMVP SEC Filings, Jul-Aug 2025PMV Pharmaceuticals, Inc. Filing Archive - Stock Titan
PMV Pharmaceuticals stock gains as biotech peers advance - ad-hoc-news.de
PMV Pharmaceuticals stock gains on HC Wainwright buy rating and 5 dollar target - ad-hoc-news.de
PMVP Reiterated by HC Wainwright & Co. -- Price Target Maintained at $5.00 - GuruFocus
PMV Pharmaceuticals Prices Oversubscribed $50.8 Million Offering - TipRanks
PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push - Yahoo Finance
PMV Pharmaceuticals (PMVP) Announces $50.8M Oversubscribed Offering Amid Mixed Market Signals - GuruFocus
PMV Pharma Prices $50.8 Million Public Offering of Common Stock, Pre-Funded Warrants and Accompanying Warrants - Quiver Quantitative
PMV Pharma Prices $50.8 Million Public Offering of Common Stock, Pre-Funded Warrants and Accompanying Warrants - Quiver Quantitative
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities - GlobeNewswire
PMV Pharmaceuticals (PMVP) Updates Interim Ovarian Cancer Trial Results Amid Valuation Challenges - GuruFocus
PMV Pharmaceuticals Highlights Promising Phase 2 Ovarian Data - TipRanks
PMV Pharmaceuticals reports 46% ORR in ovarian cohort, plans NDA filing in Q1 2027 - TradingView
PMV Pharma Announces Proposed Public Offering of Securities - GlobeNewswire
PMV Pharmaceuticals, Inc. Announces Updated Interim Ovarian Cancer Data for Rezatapopt Monotherapy From PYNNACLE Phase 2 Pivotal Trial - marketscreener.com
PMV Pharmaceuticals Announces Updated Promising Rezatapopt - GlobeNewswire
PMV Pharmaceuticals Reports Updated Rezatapopt Ovarian Cancer Data, Commences Offering - Yahoo Finance
Ovarian cancer trial reports a 46% response rate; FDA filing planned - Stock Titan
PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial - Yahoo Finance
ETFs Investing in PMV Pharmaceuticals, Inc. Stocks - TradingView
PMV (PMVP) Watch: Moves 1.15% Higher to $1.31; Price Context: Price Remains Between $1.24 Support and $1.38 Resistance in the Latest SessionValue Factor - vinanet.vn
Finanzdaten der Pmv Pharmaceuticals Inc-Aktie (PMVP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pmv Pharmaceuticals Inc-Aktie (PMVP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 10% Owner |
Oct 23 '25 |
Sale |
1.52 |
1,000,000 |
1,520,000 |
4,975,291 |
| OrbiMed Private Investments V, | Shareholder |
Oct 23 '25 |
Proposed Sale |
1.52 |
1,000,000 |
1,520,000 |
0 |
1.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):